Jane Robertson, MD, Global Product Vice President at AstraZeneca, describes the mechanism of action of the PARP inhibitor olaparib.
Jane Robertson, MD
Advertisement
Articles by Jane Robertson, MD
Advertisement
Latest Updated Articles
The Mechanism of Action of OlaparibPublished: July 30th 2013 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
